Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Astellas Pharma Inc
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male patients diagnosed with metastatic prostate cancer
Initiated apalutamide or enzalutamide for the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Initiation date of first treatment defines the index date.
Index date on or after 1 January 2020
Evidence of androgen deprivation therapy (ADT) use between 90 days prior to the index date and 6 months following the index date
Age ≥18 years on the index date -≥6 months of clinical activity following the index date, unless the patient died
You may not be if
Evidence of castration-resistance prior to the index date
Received chemotherapy, androgen receptor pathway inhibitor, radiopharmaceuticals, immunotherapy, PARP inhibitor, or estrogens prior to the index date
Evidence of ADT use between 1 year and 91 days prior to the index date
Had a prior history of other cancers
Clareo Health | A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
